This study evaluated the effectiveness, proper dosage and possible response of OMALIZUMAB (Biologics) for Chronic Idiopathic Urticaria (CIU) patients in KSA with antihistamine refractory CIU disease related quality of life. METHODS: The study was prospective and descriptive in nature. Omalizumab was used in those patients who did not respond to up dosing of Antihistamine, steroids and cyclosporine. Omalizumab is recombinant humanized monoclonal antibody against human IgE and has good safety profile due to biological nature of the drug. All patients administered omalizumab must be observed for 2 hours for adverse effects. Six month's trial of omalizumab 300 mg every 4 weeks, among patients with CIU. Total 26 patients with mean age 48 including both sexes. RESULTS: Out of 26 patients, 22 patients (84%) responded well to 300 mg omalizumab injection every month, whereas 4 patients need up dosing more than 300 mg .In 300 mg group eight patients achieved complete symptoms control without antihistamine intake and others required antihistamine without prednisolone and cyclosporine .Though 3 patients didn't achieved complete absence of symptoms, cyclosporine and oral corticosteroids could be discontinued. Only 1 patient reported adverse effect like Headache, Dizziness and fatigue CONCLUSIONS: Omalizumab at an initial dosage of 150 mg was not effective treatment in CIU up dosing to 300 mg was required to achieve satisfactory outcomes. It can be used after failure of other therapies. Omalizumab binds with free IgE antibodies and reduces the circulating levels of free IgE. This reduction in free IgE prevents mast cell degranulation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.